Drug Trial Radar · NCT07599761
A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
12
Actual
Start
May 7, 2026
Primary completion
Sep 3, 2026
Study completion Sep 3, 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- May 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the effect of repeated doses of itraconazole on the single dose pharmacokinetics (PK) of ABBV-722.
Conditions
- Healthy Volunteers
Interventions
ABBV-722Drug
Oral Tablet
ItraconazoleDrug
Oral Capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax) of ABBV-722Time frame: Up to Day 8 in Period 1 and Up to Day 14 in Period 2
- Time to Cmax (Tmax) of ABBV-722Time frame: Up to Day 8 in Period 1 and Up to Day 14 in Period 2
- Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of ABBV-722Time frame: Up to Day 8 in Period 1 and Up to Day 14 in Period 2
- Area Under the Plasma Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of ABBV-722Time frame: Up to Day 8 in Period 1 and Up to Day 14 in Period 2
- Terminal Phase Elimination Rate Constant (β) of ABBV-722Time frame: Up to Day 8 in Period 1 and Up to Day 14 in Period 2
- Terminal Phase Elimination Half-Life (t1/2) of ABBV-722Time frame: Up to Day 8 in Period 1 and Up to Day 14 in Period 2
- Number of Participants with Adverse Events (AEs)Time frame: Up to Approximately 45 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Acpru /Id# 282143
Grayslake, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.